Phase 4
N=40
Zonisamide vs. Placebo in the Treatment of Alcohol Dependence
Alcoholism · Alcohol Abuse · Alcohol Dependence
Bottom Line
View on ClinicalTrials.gov: NCT00595556 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcome: Primary: Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week — -.30; -.20 Days/week — p=.012
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- zonisamide (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- UConn Health
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week |
-.30; -.20 | .012 sig |
| PRIMARY Weekly Rate of Change in Abstinent Days |
0.17; 0.13 | .94 |
| SECONDARY Change in Number of Drinks Per Week by Week |
-2.2; -1.4 | .004 sig |
| SECONDARY Change in the Urge to Drink Alcohol as Measured by the Alcohol Urge Questionnaire (AUQ) |
-1.4; -0.6 | .006 sig |
| SECONDARY Change in Gamma-glutamyl Transferase (GGT) Concentration |
8.4; 2.9 | .3 |
Summary
This is a pilot study designed to examine the potential efficacy and tolerability of zonisamide compared to placebo for the treatment of alcohol dependence.
Eligibility Criteria
Inclusion Criteria
- age 18 to 65 years, inclusive
- current Diagnostic & Statistical Manual of Mental Disorders 4th ed (DSM-IV) alcohol dependence (within the past month)
- have 2 heavy drinking days per week during the period between screening and baseline (defined as >4 standard drinks per day for males, and >3 standard drinks per day for females)
- able to read at the eighth grade or higher level and show no evidence of significant cognitive impairment
- if a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or who is less than two years postmenopausal), must be non-lactating, practicing a reliable method of birth control including barrier method; and have a negative serum pregnancy test prior to initiation of treatment
- be willing to provide signed, informed consent to participate in the study
Exclusion Criteria
- have a current, clinically significant physical disease or abnormality (i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities such as hepatic aminotransferase levels greater than 300% of the uper limit of normal or direct bilirubin levels 150% of the upper limit of normal) on the basis of medical history, physician examination, or routine laboratory evaluation. Serum creatinine level of > 1.2 mg/dl will also be exclusionary. Other specific exclusionary disorders include:
- patients with a history of renal calculi
- patients with a history of hypersensitivity to zonisamide or any sulfonamide, Stevens-Johnson Syndrome, penicillin allergy, or history of any severe drug allergic reaction
- patients with a significant history of systemic autoimmune disease such as lupus erythematosis, fibromyalgia, or rheumatoid arthritis
- patients with a current blood dyscrasia or a history of such, with the exception of a remote history of iron deficient anemia
- have a serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, panic disorder, or substantial suicide or violence risk) on the basis of history or psychiatric examination
- current dependence on opioids or benzodiazepines or other sedatives will also be exclusionary
- are considered by investigators to be clinically inappropriate for study participation
- because individuals with a history of seizure disorder could potentially be at increased risk of experiencing a seizure due to their drinking, such individuals will also be excluded
- have participated in another pharmacotherapy study in the past thirty days
Data sourced from ClinicalTrials.gov (NCT00595556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.